Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Addex Therapeutics (ADXN) EPS (Weighted Average and Diluted) (2022 - 2023)

Historic EPS (Weighted Average and Diluted) for Addex Therapeutics (ADXN) over the last 1 years, with Q4 2024 value amounting to -$242.3 million.

  • Addex Therapeutics' EPS (Weighted Average and Diluted) changed N/A to -$242.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$242.3 million, marking a year-over-year change of. This contributed to the annual value of $176.4 million for FY2024, which is 11315907251903.46% up from last year.
  • Addex Therapeutics' EPS (Weighted Average and Diluted) amounted to -$242.3 million in Q4 2024.
  • Addex Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $110.3 million for Q2 2024, and its period low was -$242.3 million during Q4 2024.